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Objectives: Shivering is very distressing for the patient therefore, control of postspinal shivering is essen-
tial for proper perioperative care. This study was designed to compare the efficacy, safety and cost effec-
tiveness of Dexmedetomidine and Nalbuphine in the treatment of postspinal shivering.
Methods: In this prospective, randomized, double-blind, placebo controlled study, 75 American Society of
Anesthesiologists Grade I and II females scheduled for vaginal hysterectomy under spinal anesthesia, who
developed shivering grade 3 or 4 were included. The patients were randomized into three groups of 25
patients each to receive either Nalbuphine 0.07 mg/kg (group N) or Dexmedetomidine 0.5 lg/kg (group
D) or saline (group C) as a slow intravenous bolus for treatment of shivering. Onset of shivering, grade of
shivering, time for cessation, response rate, recurrence, hemodynamic parameters and adverse effects
were observed at scheduled intervals.
Results: It was observed that the mean response time for control of shivering was significantly less in
Group D (1.97 ± 0.61 min) compared to Group N (3.56 ± 0.82 min) and Group C (12.4 ± 3.74 min).
Success rate in Group D was 100% compared to 92% in Group N and 32% in Group C. Relapse of shivering
was observed more in patients of Group N (8.7%) as compared to Group D (0%) while shivering reap-
peared in 75% of patients who responded to saline treatment. Among the side effects, sedation was found
in both groups N and D. Bradycardia and hypotension were more frequent in Dexmedetomidine group
although none of the patients required treatment. Pain during injection was an outstanding complaint
in Nalbuphine group.
Conclusion: Both Nalbuphine and Dexmedetomidine control shivering effectively, but Dexmedetomidine
seems to be a better choice than Nalbuphine for treatment of postspinal shivering due to its shorter
response time, lower recurrence rate and associated sedation. Meanwhile, Nalbuphine offers more hemo-
dynamic stability and lower costs.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Shivering is a relatively common problem encountered during
the perioperative period. It is reported in 40–70% of patients
undergoing surgery under regional anesthesia [1].
Along with nausea and vomiting, postanesthesia shivering is
one of the leading causes of discomfort for patients. Shivering
not only adds psychological stress to the patient but also physio-
logically leads to an increase in O2 consumption by 200–500%,
and increased carbon dioxide production which may lead to prob-lems in patients with existing intrapulmonary shunts, fixed cardiac
output, or limited respiratory reserve [1].
The primary cause of postanasthesia shivering is perioperative
hypothermia. However, shivering associated with cutaneous
vasodilatation (non-thermoregulatory shivering) also occurs [2].
As shivering has been reported in normothermic patients, other
mechanisms such as inhibited spinal reflexes, apprehension,
decreased sympathetic activity, pyrogen release, adrenal gland
suppression, and respiratory alkalosis have been suggested [3].
Kranke et al. [4] extrapolated data from a meta-analysis regard-
ing medications and dosing practices and concluded that prophy-
laxis against perioperative shivering is not cost effective, and that
treatment strategies should start with external warming and then
progress to pharmacologic interventions.
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ing the threshold shivering temperature while raising the skin
temperature and improving the comfort of the patient. However,
it is less efficient than pharmacological agents as skin temperature
only contributes 20% to control of vasoconstriction and shivering
[5].
Meperidine is probably the most efficient antishivering drug
used. It is the only drug that decreases the shivering twice as much
as the vasoconstriction threshold [6.1 C lg1 ml vs 3.3 -
C lg1 ml with a slope ratio of 1.85] [6].
It has been postulated that meperidine’s special anti-shivering
effect is mediated by its j-receptor activity [7]. Nalbuphine is a
semisynthetic, mixed agonist antagonist opioid that has the char-
acteristics of l-antagonist and j-agonist activities. It has a high
affinity for j-opioid receptors in the central nervous system [8].
A clinically important contribution of j receptors is supported by
the observation that meperidine reduces the intensity of cold-
induced shivering even in the presence of moderate doses of nalox-
one, which presumably blocks l receptors while having little effect
on the relatively resistant j receptors [9].
It was also postulated that the special antishivering effect of
meperidine is mediated by its central a2-activity [10]. Dexmedeto-
midine and meperidine are both central a2-receptor agonists.
Dexmedetomidine and meperidine additively reduced the shiver-
ing threshold in healthy adults by 2 C, with only minimal seda-
tion or respiratory toxicity [11]. Dexmedetomidine comparably
reduces the vasoconstriction and shivering thresholds, thus sug-
gesting that it acts on the central thermoregulatory system rather
than preventing shivering peripherally [12]. It also acts by blocking
a2 receptors at the locus ceruleus of the brainstem and spinal cord
thus causing sedation and analgesia [13].
Due to undesired side effects and lack of availability of meper-
idine we chose to study Nalbuphine and Dexmedetomidine which
are more readily available.
The primary outcome of this prospective double-blind, random-
ized, controlled study was to clinically compare the ability of either
drug to effectively abolish postspinal shivering (time to cessation
of shivering). Secondary outcome includes hemodynamic effects,
complications, side effects and cost effectiveness of Dexmedeto-
midine compared with those of Nalbuphine for treatment of shiv-
ering in women undergoing hysterectomy under spinal anesthesia.2. Patients and methods
After obtaining approval from our hospital’s ethics committee,
this prospective double-blind, randomized, controlled study was
conducted at the department of Obstetrics and Gynecology, Faculty
of Medicine, El- Minia University Hospital from December 2014 to
June 2015. The study involved 75 consecutive ASA class I & II
patients scheduled for elective vaginal hysterectomy with or with-
out repair of cystocele and/or rectocele. All patients gave written
informed consent.
Excluded from the study were patients with known hypersensi-
tivity to Dexmedetomidine or Nalbuphine, known history of alco-
hol or substance abuse, hyperthyroidism, cardiovascular diseases,
psychological disorder, severe diabetes, gross neurologic impair-
ment, serum creatinine >1.3 mg/dl, ages <35 or >85 yr, preopera-
tively determined need for postoperative intensive care, any
conditions which would preclude from conducting regional anes-
thesia, such as bleeding tendencies (due to either primary disease
or the use of anticoagulant drugs), and a likelihood of conversion to
an abdominal approach.
A 2-operator technique was employed to maintain blinding. The
study solutions were prepared by an investigator who was not
involved in patient handling. Patients who developed post–spinalPlease cite this article in press as: Megalla SA, Mansour HS. . Egypt J Anaesthshivering were randomly (sealed envelope technique) allocated
to one of three groups Group C: received an intravenous (iv) bolus
of 0.9% normal saline (10 ml) administered over 2 min. Group N:
received an intravenous (iv) bolus of 0.07 mg/kg nalbuphine (Nalu-
fin, Amoun, 20 mg/ml) administered over 2 min. Group D: received
an iv bolus of 0.5 lg/kg Dexmedetomidine hydrochloride (Pre-
cedex, Hospira, vial 200 mcg/2 ml) administered over 2 min. All
treatment drugs were diluted with 0.9% saline to a 10 ml volume.
The anesthesiologist conducting the case and recording the data
was unaware of the preparation administered. After standard anes-
thesia monitors were applied, Lactated Ringer’s solution (10 ml/kg)
was infused. With the patient in the sitting position, the lumbar
region was prepped with Betadine. A 25 gauge Quincke’s needle
was introduced at L3-4 interspace. After free flow of cerebrospinal
fluid was confirmed, Bupivacaine 0.5% (15 mg) was injected
intrathecally and blockade up to T9-10 dermatome was achieved.
All operating theatres in which the operations were performed
maintained constant humidity (70%) and an ambient temperature
of around 21 C to 23 C. Oxygen was administered to all the
patients at a rate of 3 L/min via nasal cannula. Intraoperatively,
patients were covered with 2 layers of surgical drapes and a cotton
blanket postoperative. No means of active re-warming were used.
Intravenous fluids and anesthetic drugs were administered at room
temperature.
Standard monitoring of pulse rate, noninvasive blood pressure
(NIBP), oxygen saturation (SpO2), body temperature (axillary) were
recorded before the commencement of surgery and thereafter
every 5 min from the baseline (i.e. subarachnoid block), for the first
hour; and every 15 min, for the rest of the observation period.
Grading of shivering was done as per Wrench et al. [14] which
is: Grade 0: No shivering. Grade 1: One or more of the following:
Piloerection, peripheral vasoconstriction, peripheral cyanosis but
without visible muscle activity. Grade 2: Visible muscle activity
confined to one muscle group. Grade 3: Visible muscle activity in
more than one muscle group. Grade 4: Gross muscle activity
involving the whole body.
Patients who developed either grade 3 or 4 shivering were
included in the study. The attending anesthetist recorded the time
in minutes at which shivering started after spinal anesthesia (onset
of shivering), severity of the shivering (grade), time to disappear-
ance of shivering in minutes (response time) and success rate
(shivering ceased after treatment within 15 min). Duration of sur-
gery was noted, and duration of spinal anesthesia was recorded by
assessing spontaneous recovery of sensory block using pin-prick
method and observing spontaneous movements of limbs in the
postoperative period. If the shivering did not subside by 15 min,
the treatment was considered ineffective. Recurrence of shivering
was also noticed until the patient left the operating theatre.
Patients who did not respond or in whom recurrence of shivering
occurred were treated with Meperidine 30 mg.
Side effects like nausea, vomiting, bradycardia (<50/min),
hypotension (>20% of baseline), pain during injection and sedation
score were recorded. Sedation score was assessed with a four-point
scale as per Filos et al. [15] 1: Awake and alert. 2: Somnolent, but
responsive to verbal stimuli. 3: Somnolent, arousable to physical
stimuli. 4: Unarousable.
Bradycardia, hypotension and vomiting were treated with atro-
pine, ephedrine and granisetron, respectively, in titrated doses
when required.3. Sample size calculation
Sample size calculation was done using the equation provided
by Eng, 2003 [16]. The means of time taken for cessation of post-
spinal shivering after treatment with either Nalbuphine or(2016), http://dx.doi.org/10.1016/j.egja.2016.10.012
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study. For a difference between the means of both drugs to be of
value we hypothesized 180 s and a standard deviation of 180 s.
Aiming for a statistical power of 90% and a significance criterion
of 0.05, the calculated sample was 21 patients in each group. To
reduce the possibility of dropouts, we enrolled 25 patients per
group.3.1. Statistical analysis
Quantitative data were presented as mean ± standard deviation.
Continuous variables were analyzed using one-way ANOVA, and
Bonferroni post hoc tests were used to correct for multiple compar-
isons. While qualitative data were presented by frequency distri-
bution and chi square test was used. The package SPSS 18.0
(SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
P < 0.05 was considered statistically significant.4. Results
Seventy-five patients undergoing vaginal hysterectomy under
spinal anesthesia completed this study (Fig. 1). Patients character-
istics and duration of surgery in all the three groups were compa-
rable (Table 1). All the groups were comparable with regard to time
of onset and grading of shivering. Mean time to cessation of shiv-
ering after injection of drug was 1.97 ± 0.61 min in group D while
it was 3.56 ± 0.82 min in group N and 12.4 ± 3.74 min in group C
which was statistically significant (p value < 0.0001) on intergroupFigure 1. Flow Diagram
Please cite this article in press as: Megalla SA, Mansour HS. . Egypt J Anaesthcomparison (Table 2). Shivering was controlled in 100% of patients
in Dexmedetomidine group compared to 92% of patients in Nal-
buphine group and 32% in normal saline group. A statistically sig-
nificant difference (p value < 0.0001) in success rate was observed
when group N and group D were compared to group C (Table 3).
Recurrence of shivering was observed in 2/23 patients (8%) in
group N, 6/8 patients (75%) in group C compared to none in group
D. This difference in relapse rate was insignificant (p value = 0.82)
when Nalbuphine group was compared to Dexmedetomidine
group, however, statistical significance (p value < 0.0001) when
these groups were compared to control group (Table 3).
Among the side effects, one patient (4%) experienced mild nau-
sea in group D, three patients (12%) in group N and two (8%) in
group C. This was not found to be statistically significant. Fifteen
patients (60%) in group D and 14 patients (56%) in group N had
sedation grade 2, while 5 patients (20%) in group D and two
patients (8%) in group N had sedation grade 3. Three patients in
group D experienced bradycardia which was transient and did
not require treatment. Pain during injection was an outstanding
complaint in the Nalbuphine group (Table 4).
Heart rate and mean blood pressure were significantly lower in
group D compared to the other groups for a period of about 25 min
following dexmedetomidine injection (Figs. 2 and 3), but didn’t
require any treatment. Axillary temperatures and SpO2 were com-
parable in the three groups with no significant difference (Figs. 4
and 5).for participants.
(2016), http://dx.doi.org/10.1016/j.egja.2016.10.012
Table 1
Demographic data in the study groups.
Data Group C (n = 25) Group N (n = 25) Group D (n = 25) P value
Age (years) 55.38 ± 11.64 52.06 ± 13.36 53.25 ± 15.91 0.1
Weight (kg) 75.7 ± 9.5 76.2 ± 6.6 75.7 ± 10.6 0.6
Height (cm) 149.1 ± 7.3 150.9 ± 8.4 152.8 ± 5.8 0.7
ASA (I/II) 20/5 21/4 22/3 0.8
Duration of surgery (min) 94.34 ± 14.53 96.67 ± 12.8 99.32 ± 10.8 0.9
Crystalloid fluids (CC) 2226.85 ± 234.12 2150.25 ± 235.12 2175.25 ± 220.12 0.1
Shivering grade III/IV III = 16 (64%) III = 13 (52%) III = 14 (56%) 0.8
IV = 9 (36%) IV = 12 (48%) IV = 11 (44%)
Table 2
Assessment of shivering and response time.
Group C (n = 25) Group N (n = 25) Group D (n = 25) P value
Onset of shivering (min) 18.45 ± 10.76 18.00 ± 9.37 18.50 ± 11.02 0.95
Time interval from treatment to cessation of shivering (min) 12.4 ± 3.74 3.56 ± 0.82** 1.97±0.61**,# 0.0001
One way ANOVA -test between the three groups followed by Bonferroni post hoc test.
# Significance between Nalbuphine group and Dexmedetomidine group. p = 0.04.
** Significance between Control group and group N, D. p = 0.0001.
Table 3
Treatment outcome of shivering in the three groups (number and %).
Data Group C (n = 25) Group N (n = 25) Group D (n = 25) P value
Success rate 8/25 23/25 25/25 0.0001*
(32%) (92%) (100%)
Recurrence after success 6/8 2/23 0/25 0.0001*
(75%) (8.7%) (0%)
Failure 17/25 2/25 0/25 0.0001*
(68%) (8%) (0%)
Group C = Control, Group N = Nalbuphine, Group D = Dexmedetomidine.
One way ANOVA followed by Post Hoc test was used for analysis.
* Significance between group C and groups N and D.
Table 4
Complications in the three groups (number and %).
Complications Group C (n = 25) Group N (n = 25) Group D (n = 25) P value
C/N C/D N/D
Nausea 2(8%) 3(12%) 1(4%) 1.0 1.0 0.921
Sedation
Grade 1 25 9 5 0.0001 0.0001 0.386
Grade 2 0 14 15 0.0001 0.0001 1.0
Grade 3 0 2 5 0.972 0.046 0.422
Grade 4 0 0 0
Bradycardia 0 0 3 1.0 0.090 0.090
Hypotension 2 2 3 1.0 1.0 1.0
Pain on injection 0 20(80%) 0 0.0001 1.0 0.0001
Group C = Control, Group N = Nalbuphine, Group D = Dexmedetomidine.
ANOVA followed by Post Hoc test to compare the three groups. C/N: group C versus group N C/D: group C versus group D N/D: Group N versus group D.
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The results of the present study showed the superiority of
dexmedetomidine over nalbuphine in treatment of postspinal
shivering as shown by a shorter response time, higher success rate
and less recurrence.
In our study, a dose of 0.07 mg/kg nalbuphine was used. This
dose was chosen on the basis that equianalgesic doses of nal-
buphine versus meperidine is 1:5 [8] and, Wrench et al. suggested
that the minimal effective dose of meperidine for treating post-
spinal shivering is approximately 0.35 mg/kg [14]. This dose effec-
tively controlled shivering in 92% of patients with only an 8.7%
recurrence rate in the present study.Please cite this article in press as: Megalla SA, Mansour HS. . Egypt J AnaesthKyokong et al. used 0.05 mg/kg to treat shivering following
spinal anesthesia for cesarean section. Nalbuphine showed a suc-
cess rate of 81.4% and a 15.8% recurrence rate [17]. This difference
may be attributed to the smaller dose used and the much younger
mean age of their study group 29.93 ± 5.3 vs 52.06 ± 13.36 yrs in
our groups.
Gotz et al., used 10 mg nalbuphine to treat shivering following
general anesthesia and found that nalbuphine suppressed postop-
erative shivering as effectively and timely as meperidine [18].
Wang et al., used a dose of 0.08 mg/kg to treat shivering following
general anesthesia, nalbuphine produced a rapid and potent
antishivering effect similar to that observed with meperidine [19].
In the present study, Dexmedetomidine 0.5 lg/kg produced a
rapid and effective control of shivering in 100% of patients with(2016), http://dx.doi.org/10.1016/j.egja.2016.10.012
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
be
at
 /
 m
in
 
Mean Heart Rate 
Group C 
Group N 
group D 
Figure 2. Perioperative changes in heart rate.
0 
20 
40 
60 
80 
100 
120 
Group D Group N Group C 
Figure 3. Perioperative changes in mean blood pressure.
35.6 
35.8 
36 
36.2 
36.4 
36.6 
36.8 
37 
37.2 
Group D 
Group N 
Group C 
Figure 4. Changes in corrected axillary temperature over time.
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meta-analysis which indicated the minimum effective dose for
controlling postoperative shivering to be 0.5 lg/kg [20].
Mittal et al. used dexmedetomidine 0.5 lg/kg for treatment of
post spinal shivering. Dexmedetomidine controlled shivering
in100% of patients and time for cessation of shivering wasPlease cite this article in press as: Megalla SA, Mansour HS. . Egypt J Anaesth2.52 ± 0.44 min, recurrence occurred in 4% of patients. The inci-
dence of sedation was 21.4% [21].
Blaine Easley et al. reported that dexmedetomidine 0.5 lg/kg as
a single IV bolus dose over 3–5 min was effective for treatment of
postanesthesia shivering in children following general anesthesia.
Cessation of shivering occurred within 5 min after the completion(2016), http://dx.doi.org/10.1016/j.egja.2016.10.012
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Figure 5. Oxygen saturation over time.
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shivering and no adverse effects [22].
Sedation accompanied both nalbuphine (64%) and dexmedeto-
midine (80%) which is actually beneficial during surgery under
spinal anesthesia.
Regarding cost/effectiveness, the price of Dexmedetomidine in
Egypt (Precedex, 100 lg/ml, 2 ml vial, Hospira) is 170 £ compared
to £7 for Nalbuphine (Nalufin 20 mg/ml, Amoun). However, Pre-
cedex is a multidose vial, so average patient cost for 0.5 lg/kg
would be around £40–45.
A limitation of this study is that we could not measure the core
body temperature. For measurement of core body temperature, the
probe needs to be put in the esophagus or near the tympanic mem-
brane. Both sites were uncomfortable and unacceptable to patients
under spinal anesthesia. Rectal temperature was unaccepted by
the surgeon as it would interfere with the surgical field.
6. Conclusion
The limited availability of meperidine provoked a search for
effective alternatives. Both nalbuphine and dexmedetomidine con-
trol shivering effectively, but dexmedetomidine seems to be a bet-
ter choice than nalbuphine for treatment of postspinal shivering
due to its higher response rate, shorter response time and lower
incidence of recurrence. Meanwhile, nalbuphine offers more
hemodynamic stability and lower costs.
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